Drugs IPOs Depend o...
Health Care: Drugs
Nektar Therapeutics Inc. (NKTR: NASDAQ)
$9.81 0.48 | 5.14%
06/18/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 25.44M | 15.31M | 17.76M | 49.60M |
| Receivables | 5.80M | 4.94M | 25.10M | 4.80M |
| Inventories | 18.27M | 12.66M | 7.27M | 6.47M |
| Other Current Assets | 13.36M | 17.94M | 5.68M | 6.18M |
| Total Current Assets | 314.63M | 276.71M | 353.98M | 413.67M |
| Property, Plant & Equipment, Gross | 144.88M | 140.81M | 143.77M | 132.66M |
| Accumulated Depreciation & Depletion | 72.67M | 62.24M | 53.99M | 54.40M |
| Property, Plant & Equipment, Net | 72.22M | 78.58M | 89.77M | 78.26M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 34.44M | 174.77M | 972.00K | 7.09M |
| Total Non-Current Assets | 183.16M | 329.84M | 167.25M | 161.85M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 497.79M | 606.55M | 521.22M | 575.52M |
| Accounts Payable | 2.86M | 3.02M | 7.19M | 3.07M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 12.41M | 6.49M | 6.39M | 5.81M |
| Total Current Liabilities | 78.54M | 275.53M | 64.11M | 153.02M |
| Long Term Debt | 125.00M | 0.00 | 214.96M | 214.96M |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 235.63M | 118.62M | 134.49M | 86.38M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 372.24M | 133.21M | 366.46M | 320.14M |
| Total Liabilities | 450.77M | 408.74M | 430.56M | 473.15M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 47.02M | 197.81M | 90.66M | 102.37M |
| Common Par | 11.00K | 11.00K | 9.00K | 9.00K |
| Additional Paid In Capital | 1.62B | 1.60B | 1.35B | 1.33B |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -1.57B | -1.40B | -1.26B | -1.23B |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | -357.00K | -1.10M | 968.00K | 1.02M |
| Total Capitalization | 172.02M | 197.81M | 305.62M | 317.32M |
| Total Equity | 47.02M | 197.81M | 90.66M | 102.37M |
| Total Liabilities & Stock Equity | 497.79M | 606.55M | 521.22M | 575.52M |
| Total Common Shares Outstanding | 115.26M | 114.48M | 94.52M | 93.28M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 114.82M | 112.94M | 94.08M | 92.77M |
| Diluted Weighted Shares Outstanding | 114.82M | 112.94M | 94.08M | 92.77M |
| Number of Employees | 433 | 423 | 408 | 335 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with NKTR
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorBreakout Stocks Of The Week...
- Contributor22 Biopharma Stocks With Br...
- Contributor10 Health Care Stocks With ...
- Contributor10 Mid-Caps With Upside
- Contributor10 Pharma Stocks With Upside
- ProDriehaus Capital
- UserSUPRATRADE 7 Top Stocks for...
- UserSUPRATRADE 10 Stock Picks F...
Latest NKTR Headlines from TheStreet
- 4 Stocks Under $10 Spiking Higher 02.22.13 | 03:02 pm
- 5 Stocks Poised for Breakouts 02.01.13 | 01:02 pm
- J.P. Morgan Healthcare Confab Live Blog Day Three 01.09.13 | 10:01 am
- Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab 01.04.13 | 08:01 am
- A Buysider's Preview of Biotech's Biggest Conference 01.02.13 | 07:01 am
- AstraZeneca, Nektar Opioid Constipation Drug May Have Failed Phase III Study 11.13.12 | 10:11 am
- FDA Places New Heart-Safety Hurdle in Path of Opioid Constipation Drugs 11.12.12 | 10:11 am
- 21 Most Volatile Biopharma Stocks Closing Out 2012 11.05.12 | 06:11 am
- 5 Stocks Poised for Breakouts 09.28.12 | 01:09 pm
- Nektar Therapeutics Is a Short 09.12.12 | 07:09 am
Press Releases for NKTR
- Bayer Initiates Phase III Trial Of Investigational Inhaled Amikacin Solution (BAY41-6551T) In Mechanically Ventilated Patients With Gram-negative Pneumonia - PR Newswire 04.16.13 | 05:04 am
- Nektar Therapeutics To Present At The 33rd Annual Cowen And Company Healthcare Conference In Boston - PR Newswire 03.01.13 | 04:03 pm
- AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation - PR Newswire 02.26.13 | 06:02 am
- Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The 31st Annual J.P. Morgan Healthcare Conference In San Francisco, CA - PR Newswire 01.04.13 | 08:01 am
- Nektar To Announce Financial Results For The Third Quarter Of 2012 On Tuesday, November 13, 2012, After Close Of U.S.-Based Financial Markets - PR Newswire 11.06.12 | 05:11 pm
- Nektar Therapeutics' President And CEO, Howard W. Robin, To Present At The UBS 2012 Global Life Sciences Conference In New York City - PR Newswire 09.13.12 | 09:09 am
- Nektar To Announce Financial Results For The Second Quarter Of 2012 On Thursday, August 9, 2012, After Close Of U.S.-Based Financial Markets - PR Newswire 08.02.12 | 03:08 pm
- Nektar Therapeutics Announces Private Placement Of $125 Million Of Senior Secured Notes Due In 2017 - PR Newswire 07.10.12 | 08:07 am
- Nektar To Host Investor And Analyst R&D Day In New York City - PR Newswire 04.10.12 | 08:04 am
- Nektar Doses First Subjects In Phase 1 Clinical Study Evaluating NKTR-192, A New Short-Acting Opioid Molecule For The Treatment Of Acute Pain - PR Newswire 04.02.12 | 08:04 am
Partner Headlines for NKTR
- Nektar Announces Target-Specific Biomarkers Being Evaluated in Phase 3 BEACON Study of Etirinotecan Pegol - Benzinga 06.01.13 | 02:06 pm
- UPDATE: Bank of America Lowers Nektar Therapeutics PO, Maintains Underperform - Benzinga 11.13.12 | 09:11 am
- UPDATE: Jefferies & Company Downgrades Nektar Therapeutics to Hold, Lowers PT - Benzinga 11.12.12 | 09:11 am
- Nektar Therapeutics Says Got Positive Data from Phase 1a Study of NKTR-192 - Benzinga 09.18.12 | 09:09 am
- Long Undervalued, Is Alkermes Still A Bargain? - Seeking Alpha 03.30.12 | 09:03 am
- The Age Of Personalized Medicine Has Arrived - Seeking Alpha 03.08.12 | 09:03 am
- Company News for March 1, 2012 - Corporate Summary - Zacks 03.01.12 | 10:03 am
- What's It Going To Take To Get Salix Cheap? - Seeking Alpha 02.29.12 | 08:02 am
- Nektar Therapeutics Presents Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer - Benzinga 09.10.11 | 04:09 pm
- 10 Stocks With Bullish Momentum Backed By Strong Top Line Growth - Seeking Alpha 08.24.11 | 08:08 am
